Cargando…
Three Weekly Intra-Articular Injections of Hylan G-F 20 vs Arthrocentesis in Patients with Chronic Idiopathic Knee Osteoarthritis: A Multicenter, Evaluator- and Patient-Blinded, Randomized Controlled Trial
BACKGROUND: Knee osteoarthritis is a leading cause of disability worldwide. Symptoms can vary over time, leading to episodes of worsened symptoms known as flares. Intra-articular injection of hyaluronic acid has demonstrated long-term symptomatic relief in the broader knee osteoarthritis population,...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319210/ https://www.ncbi.nlm.nih.gov/pubmed/37408828 http://dx.doi.org/10.1016/j.curtheres.2023.100707 |
_version_ | 1785068198850199552 |
---|---|
author | Huang, Yili Lascarides, Peter Ngai, Wilson Steele, Kevin Hummer, Charles D. |
author_facet | Huang, Yili Lascarides, Peter Ngai, Wilson Steele, Kevin Hummer, Charles D. |
author_sort | Huang, Yili |
collection | PubMed |
description | BACKGROUND: Knee osteoarthritis is a leading cause of disability worldwide. Symptoms can vary over time, leading to episodes of worsened symptoms known as flares. Intra-articular injection of hyaluronic acid has demonstrated long-term symptomatic relief in the broader knee osteoarthritis population, although its use in the flare population has not been extensively examined. OBJECTIVE: To assess the efficacy and safety of 3 once-weekly intra-articular injections of hylan G-F 20 (as single and repeat courses) in patients with chronic knee osteoarthritis, including a subpopulation that experienced flare. METHODS: Prospective randomized controlled, evaluator- and patient-blinded, multicenter trial with 2 phases: hylan G-F 20 vs arthrocentesis only (control) and 2 courses vs single-course hylan G-F 20. Primary outcomes were visual analog scale (0–100 mm) pain scores. Secondary outcomes included safety and synovial fluid analysis. RESULTS: Ninety-four patients (104 knees) were enrolled in Phase I, with 31 knees representing flare patients. Seventy-six patients (82 knees) were enrolled in Phase II. Long-term follow-up was 26 to 34 weeks. In flare patients, hylan G-F 20 showed significantly more improvement than the controls for all primary outcomes except pain at night (P = 0.063). Both 1 and 2 courses of hylan G-F 20 showed significant improvements from baseline for primary outcomes with no differences in efficacy between groups in the intention-to-treat population at the end of Phase II. Two courses of hylan G-F 20 showed better improvement in pain with motion (P = 0.0471) at long-term follow-up. No general side effects were reported, and local reactions (pain/swelling of the injected joint) resolved within 1 to 2 weeks. Hylan G-F 20 was also associated with reduced effusion volume and protein concentration. CONCLUSIONS: Hylan G-F 20 significantly improves pain scores vs arthrocentesis in flare patients with no safety concerns. A repeat course of hylan G-F 20 was found to be well tolerated and efficacious. |
format | Online Article Text |
id | pubmed-10319210 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-103192102023-07-05 Three Weekly Intra-Articular Injections of Hylan G-F 20 vs Arthrocentesis in Patients with Chronic Idiopathic Knee Osteoarthritis: A Multicenter, Evaluator- and Patient-Blinded, Randomized Controlled Trial Huang, Yili Lascarides, Peter Ngai, Wilson Steele, Kevin Hummer, Charles D. Curr Ther Res Clin Exp Original Research BACKGROUND: Knee osteoarthritis is a leading cause of disability worldwide. Symptoms can vary over time, leading to episodes of worsened symptoms known as flares. Intra-articular injection of hyaluronic acid has demonstrated long-term symptomatic relief in the broader knee osteoarthritis population, although its use in the flare population has not been extensively examined. OBJECTIVE: To assess the efficacy and safety of 3 once-weekly intra-articular injections of hylan G-F 20 (as single and repeat courses) in patients with chronic knee osteoarthritis, including a subpopulation that experienced flare. METHODS: Prospective randomized controlled, evaluator- and patient-blinded, multicenter trial with 2 phases: hylan G-F 20 vs arthrocentesis only (control) and 2 courses vs single-course hylan G-F 20. Primary outcomes were visual analog scale (0–100 mm) pain scores. Secondary outcomes included safety and synovial fluid analysis. RESULTS: Ninety-four patients (104 knees) were enrolled in Phase I, with 31 knees representing flare patients. Seventy-six patients (82 knees) were enrolled in Phase II. Long-term follow-up was 26 to 34 weeks. In flare patients, hylan G-F 20 showed significantly more improvement than the controls for all primary outcomes except pain at night (P = 0.063). Both 1 and 2 courses of hylan G-F 20 showed significant improvements from baseline for primary outcomes with no differences in efficacy between groups in the intention-to-treat population at the end of Phase II. Two courses of hylan G-F 20 showed better improvement in pain with motion (P = 0.0471) at long-term follow-up. No general side effects were reported, and local reactions (pain/swelling of the injected joint) resolved within 1 to 2 weeks. Hylan G-F 20 was also associated with reduced effusion volume and protein concentration. CONCLUSIONS: Hylan G-F 20 significantly improves pain scores vs arthrocentesis in flare patients with no safety concerns. A repeat course of hylan G-F 20 was found to be well tolerated and efficacious. Elsevier 2023-06-04 /pmc/articles/PMC10319210/ /pubmed/37408828 http://dx.doi.org/10.1016/j.curtheres.2023.100707 Text en © 2023 Sanofi https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Huang, Yili Lascarides, Peter Ngai, Wilson Steele, Kevin Hummer, Charles D. Three Weekly Intra-Articular Injections of Hylan G-F 20 vs Arthrocentesis in Patients with Chronic Idiopathic Knee Osteoarthritis: A Multicenter, Evaluator- and Patient-Blinded, Randomized Controlled Trial |
title | Three Weekly Intra-Articular Injections of Hylan G-F 20 vs Arthrocentesis in Patients with Chronic Idiopathic Knee Osteoarthritis: A Multicenter, Evaluator- and Patient-Blinded, Randomized Controlled Trial |
title_full | Three Weekly Intra-Articular Injections of Hylan G-F 20 vs Arthrocentesis in Patients with Chronic Idiopathic Knee Osteoarthritis: A Multicenter, Evaluator- and Patient-Blinded, Randomized Controlled Trial |
title_fullStr | Three Weekly Intra-Articular Injections of Hylan G-F 20 vs Arthrocentesis in Patients with Chronic Idiopathic Knee Osteoarthritis: A Multicenter, Evaluator- and Patient-Blinded, Randomized Controlled Trial |
title_full_unstemmed | Three Weekly Intra-Articular Injections of Hylan G-F 20 vs Arthrocentesis in Patients with Chronic Idiopathic Knee Osteoarthritis: A Multicenter, Evaluator- and Patient-Blinded, Randomized Controlled Trial |
title_short | Three Weekly Intra-Articular Injections of Hylan G-F 20 vs Arthrocentesis in Patients with Chronic Idiopathic Knee Osteoarthritis: A Multicenter, Evaluator- and Patient-Blinded, Randomized Controlled Trial |
title_sort | three weekly intra-articular injections of hylan g-f 20 vs arthrocentesis in patients with chronic idiopathic knee osteoarthritis: a multicenter, evaluator- and patient-blinded, randomized controlled trial |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319210/ https://www.ncbi.nlm.nih.gov/pubmed/37408828 http://dx.doi.org/10.1016/j.curtheres.2023.100707 |
work_keys_str_mv | AT huangyili threeweeklyintraarticularinjectionsofhylangf20vsarthrocentesisinpatientswithchronicidiopathickneeosteoarthritisamulticenterevaluatorandpatientblindedrandomizedcontrolledtrial AT lascaridespeter threeweeklyintraarticularinjectionsofhylangf20vsarthrocentesisinpatientswithchronicidiopathickneeosteoarthritisamulticenterevaluatorandpatientblindedrandomizedcontrolledtrial AT ngaiwilson threeweeklyintraarticularinjectionsofhylangf20vsarthrocentesisinpatientswithchronicidiopathickneeosteoarthritisamulticenterevaluatorandpatientblindedrandomizedcontrolledtrial AT steelekevin threeweeklyintraarticularinjectionsofhylangf20vsarthrocentesisinpatientswithchronicidiopathickneeosteoarthritisamulticenterevaluatorandpatientblindedrandomizedcontrolledtrial AT hummercharlesd threeweeklyintraarticularinjectionsofhylangf20vsarthrocentesisinpatientswithchronicidiopathickneeosteoarthritisamulticenterevaluatorandpatientblindedrandomizedcontrolledtrial |